Fig. 2

Cytotoxicity assays in 3D and monolayer AsPCs upon treatment with olaparib and niraparib. Cytotoxicity of monolayer (left) and 3D (right) using olaparib top and niraparib bottom of: a olaparib resistant (both in monolayer and 3D) and niraparib sensitive (both in monolayer and 3D) AsPCs; b olaparib and niraparib sensitive in monolayer, and resistant in 3D AsPCs. c olaparib resistant and niraparib resistant AsPCs in monolayer and 3D; d olaparib sensitive and niraparib sensitive AsPCs in monolayer and 3D. Toxicity response was determined using two independent assays (MTT for monolayer, and WTS for 3D). Cells were treated with either olaparib (0–100 μM) or niraparib (0–100 μM) and in combination with etoposide (100 μM) 24 h after cells were seeded. Toxicity assays were performed 3 days after treatment. The cell viability was calculated relative to the 0.01% DMSO-treated control AsPCs. One representative cell viability plots from 2 independent experiments are shown. All values were expressed as the means ± S.D of the 3 replicates used in the toxicity assay